Search filters

List of works by James Chih-Hsin Yang

A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma

scientific article published on 20 July 2016

A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer.

scientific article

A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors

scientific article

A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.

scientific article

A selective ALK inhibitor in ALK-rearranged patients

scientific article published on 30 April 2013

ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.

scientific article published on 7 October 2013

Acrolein induces mtDNA damages, mitochondrial fission and mitophagy in human lung cells

scientific article published on 31 July 2017

Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI.

scientific article published on 15 December 2017

Adoptive T-cell transfer therapy and oncogene-targeted therapy for melanoma: the search for synergy

scientific article

Advanced non-small cell lung cancer in the elderly: the impact of age and comorbidities on treatment modalities and patient prognosis.

scientific article published on 22 September 2014

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases

scientific article published on 10 January 2020

Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis.

scientific article

Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations

scientific article published on 17 May 2019

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

scientific article

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

scientific article published on 12 April 2016

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial ⬇️

scientific article published on March 26, 2012

Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.

scientific article published on 30 March 2016

Autologous bone marrow transplantation for plasma cell leukemia: report of a case

scientific article published on August 1, 1992

Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients.

scientific article published in February 2018

Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment?

scientific article published on 08 April 2019

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

article

Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).

scientific article

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer

scientific article published on 25 September 2018

Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers

scientific article

Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells

scientific article

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

scientific article published on 04 June 2015

Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis

scientific article published on 21 December 2017

Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion

scientific article

Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach

scientific article published on October 2011

Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma

scientific article published on 30 September 2014

Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer

scientific article

Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors

scientific article published on 24 May 2019

Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations ⬇️

scientific article published on September 15, 1995

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.

scientific article published on 16 November 2017

Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice

scientific article published on 07 July 2016

Diarrhea associated with afatinib: an oral ErbB family blocker

scientific article published on 18 March 2013

EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer.

scientific article published on July 2013

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.

scientific article published on 22 December 2016

Enhancer remodeling and microRNA alterations are associated with acquired resistance to ALK inhibitors.

scientific article published on 18 April 2018

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis

scientific article published on 2 September 2015

Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS).

scientific article

First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials

scientific article published on 08 April 2019

First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments

scientific article published on March 2013

First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial.

scientific article published on 18 June 2014

Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.

scientific article

Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS).

scientific article

INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer

scientific article

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis

scientific article

Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides

scientific article published on 19 August 2019

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

scientific article

MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib

scientific article

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

scientific article

Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer

scientific article published on May 2016

Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lun

scientific article published on December 2015

Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy

scientific article published on 14 October 2013

Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer

scientific article published on 04 January 2013

New data on clinical decisions in NSCLC patients with uncommon EGFR mutations

scientific article

Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma

scientific article published on 20 July 2011

Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cells ⬇️

scientific article published on October 31, 2012

Opportunities of circulating tumor DNA in lung cancer

scientific article published on 15 July 2019

Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations

scientific article published on January 2011

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

scientific article

Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report

scientific article published on 11 February 2019

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

scientific article published on 06 December 2019

Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies

scientific article published on 23 July 2019

Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study

scientific article published on 14 December 2017

Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors

scientific article published on 9 May 2017

Overview of current systemic management of EGFR-mutant NSCLC.

scientific article published in January 2018

Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study

scientific article published on 25 August 2018

Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer

scientific article published on August 2011

Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients

scientific article

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

scientific article

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer

scientific article published on 29 August 2018

Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas

scientific article published on 02 July 2013

Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC.

scientific article published on October 2011

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer

scientific article published on 31 October 2016

Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer

scientific article published on 14 October 2019

Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer

scientific article published on 25 June 2019

Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size

scientific article

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).

scientific article published on 29 September 2017

Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer

scientific article

Reply to E.R. Haspinger et al.

scientific article

Reply to F. De Marinis et al.

scientific article

Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer

scientific article published on 19 December 2016

Safety of gefitinib in non-small cell lung cancer treatment

scientific article published on 21 May 2016

Scientific Advances in Thoracic Oncology 2016.

scientific article published on 27 May 2017

Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer

scientific article

Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer

scientific article published on 10 April 2019

Small-Cell Lung Cancer Treatment: Where is the Target? ⬇️

scientific article published on 01 September 2012

Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers

scientific article published in November 2017

Striatal Dopamine Dynamics Are Altered Following an Intranigral Infusion of Iron in Adult Rats ⬇️

scientific article published on April 1, 1998

Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).

scientific article published in February 2013

Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations

scientific article

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer

scientific article published on 21 October 2019

Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies

scientific article published on 13 November 2019

Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?

scientific article

Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy

scientific article

Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology

scientific article published on 27 December 2013

Paulina is supported by:

About Paulina

Help